title: Immobilization of Rocky Mountain elk with Telazol and xylazine hydrochloride, and antagonism by yohimbine hydrochloride.
abstract: Ten trapped Rocky Mountain elk (Cervus elaphus nelsoni) were successfully immobilized with a combination of 500 mg Telazol and 60 mg xylazine hydrochloride (HCl) from 9 July to 25 August 1993 in Custer State Park, South Dakota (USA). Mean (SD) dosages of 2.5 (0.6) mg/kg Telazol and 0.3 (0.1) mg/kg xylazine HCl, respectively, were administered, resulting in a mean (SD) induction time of 4.6 (0.8) min. Induction time varied with weight and dosage. Respiratory rate (breaths/min) increased following injection of Telazol and xylazine HCl and remained elevated or continued to increase through 10 min post-injection and then declined. There were no mortalities in this study. Forty mg of yohimbine HCl was used as an antagonist in eight elk, resulting in a mean (SD) recovery time of 14.0 (9.9) min when administered intravenously (n = 6), and 124.7 (9.5) min when given intramuscularly (n = 2). Recovery time varied with weight and dosage of yohimbine. Elk given 2.1 to 2.6 mg/kg Telazol and 0.1 to 0.3 mg/kg xylazine HCl responded to yohimbine HCl when administered intravenously.
authors.affiliation: Department of Wildlife and Fisheries Sciences, South Dakota State University, Brookings 57007, USA.
authors.forename: J J
authors.initials: JJ
authors.lastname: Millspaugh
authors.forename: G C
authors.initials: GC
authors.lastname: Brundige
authors.forename: J A
authors.initials: JA
authors.lastname: Jenks
authors.forename: C L
authors.initials: CL
authors.lastname: Tyner
authors.forename: D R
authors.initials: DR
authors.lastname: Hustead
mesh_terms: D000777:Anesthetics / Q000008:administration & dosage / Q000037:antagonists & inhibitors; D000818:Animals; D003670:Deer / Q000502:physiology*; D004338:Drug Combinations; D005260:Female; D007103:Immobilization; D007273:Injections, Intramuscular / Q000662:veterinary; D007275:Injections, Intravenous / Q000662:veterinary; D008297:Male; D012119:Respiration / Q000187:drug effects; D013565:Sympatholytics / Q000008:administration & dosage / Q000494:pharmacology*; D013992:Tiletamine / Q000008:administration & dosage / Q000037:antagonists & inhibitors; D013997:Time Factors; D014991:Xylazine / Q000008:administration & dosage / Q000037:antagonists & inhibitors; D015016:Yohimbine / Q000008:administration & dosage / Q000494:pharmacology*; D015041:Zolazepam / Q000008:administration & dosage / Q000037:antagonists & inhibitors
chemical_list: D000777:Anesthetics; D004338:Drug Combinations; D013565:Sympatholytics; C006131:tiletamine, zolazepam drug combination; D014991:Xylazine; D015016:Yohimbine; D013992:Tiletamine; D015041:Zolazepam